Numerous protocols have been described that produce neural retina from human pluripotent stem cells (hPSCs), many of which are based on the culture of 3D organoids. While nearly all such methods yield at least partial segments of highly mature-appearing retinal structure, variabilities exist within and between organoids that can change over a protracted time course of differentiation.
David Gamm
UW researcher using stem cells to create ‘spare part’ for blindness
To mark the 20th anniversary of the stem cell discovery at UW-Madison, the Wisconsin State Journal featured a series of stories on stem cell research, highlighting the work of Waisman Center investigators David Gamm, Anita …
Years after promise of stem cells seemed to be fading, clinical trials underway
A story in the Milwaukee Journal Sentinel reflects on the history of stem cells and its future direction. Two decades after the first stem cell breakthrough, the promising biological discovery is beginning to take steps …
Scientists seek to improve quality control for genome editing therapies in the eye
Waisman Center investigator David Gamm, MD, PhD, and affiliate Krishanu Saha, PhD, are part of a team of scientists at the University of Wisconsin- Madison who were recently granted a major award from the National …
David Gamm, MD, PhD
Cell type-specific investigations commonly employ gene reporters or single-cell (sc) analytical techniques. However, reporter line development is arduous and generally limited to a single gene of interest, while scRNA-seq frequently yields equivocal results that preclude definitive cell identification.
A decade after stem cell feat, research ramps up
A decade after scientists announced the development of induced pluripotent stem cells, Waisman investigators, including Su-Chun Zhang and David Gamm, continue to use these cells to research and develop potential therapies for several disorders and conditions, such as ALS, Parkinson’s disease, spinal cord injury, and macular degeneration.
David Gamm, MD, PhD
Title: Interconversion of early VSX2WT and VSX2R200Q hiPSC-OV phenotypes by pharmacological manipulation of WNT signaling. Legend: Pharmacological manipulation of the WNT signaling pathway during in vitro retinogenesis in hiPSCs affects the cell fate decision between …
David Gamm, MD, PhD
Title: Pharmacological modulation of photoreceptor outer segment degradation in Best disease patient-derived hiPSC-RPE Legend: (a) Representative western blot analysis comparing the amount of the POS protein RHO in untreated and VPA-treated (500 µmol/l) BD hiPSC-RPE at …
UW Eye Researchers Publish Second Study of Stem Cells and Blinding Eye Disease
A team of eye researchers at the University of Wisconsin-Madison have used a custom stem cell model of a rare but blinding eye disease to test whether a commonly used drug might offer hope for treatment.
Vision Research Month
June is Vision Research Awareness Month and the Waisman Center is home to a comprehensive vision research program led by David Gamm, MD, PhD. Gamm, a Waisman Center investigator, associate professor of ophthalmology and visual sciences, and Director of the McPherson Eye Research Institute, studies human retinal development and potential therapies for retinal degenerative diseases.